Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Rosa roxburghii* (also known as chestnut rose or Cili) is a medicinal plant from the Rosaceae family, native to China and widely used in traditional Chinese and Miao ethnomedicine. It is characterized by an exceptionally high content of bioactive compounds, including vitamin C, superoxide dismutase (SOD), polyphenols, flavonoids, triterpenoids, and polysaccharides. Pharmacological research has demonstrated that *Rosa roxburghii* extracts possess potent antioxidant, anti-inflammatory, immunomodulatory, and metabolic-regulating properties. It has been investigated for its therapeutic potential in managing various conditions, including digestive disorders (such as gastric ulcers and ulcerative colitis), type 2 diabetes, hyperlipidemia, hypertension, and certain cancers. While available as a botanical extract for research purposes, it is primarily classified as a natural product or nutraceutical rather than a conventional pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rosa roxburghii.